Boosting the influenza vaccine schedule in children with cancer: a prospective open-label study

Area of Science:

• Immunology
• Pediatric Oncology
• Vaccinology

Background:

• Standard influenza vaccination guidelines may be insufficient for immunocompromised children.
• Children undergoing chemotherapy exhibit an attenuated immune response to vaccines.

Purpose of the Study:

• To evaluate the safety and efficacy of a boosted influenza vaccine schedule in pediatric cancer patients.
• To assess the humoral immune response to an intensified vaccination regimen.

Main Methods:

• A prospective, open-label study was conducted in children undergoing cancer treatment.
• Participants received either three doses (age <9 years) or two doses (age ≥9 years) of influenza vaccine, spaced at least 4 weeks apart.

Main Results:

• The boosted schedule was well-tolerated with no serious adverse events.
• Significant improvements in geometric mean antibody titers were observed for influenza A/H1N1, A/H3N2, and B/Washington strains.
• The enhanced schedule led to a statistically significant increase in antibody levels against key influenza strains.

Conclusions:

• A boosted influenza vaccine schedule is a safe and effective strategy for children undergoing cancer treatment.
• This approach enhances the humoral immune response, providing improved protection against influenza.
• The findings support the implementation of this intensified vaccination schedule to safeguard immunocompromised children.